Comparison of Efficacy and Safety of Lupin’s Pegfilgrastim with Neulastim® as an Adjunct to Chemotherapy in Patients with Non Myeloid Malignancies: A Randomised Phase III Clinical Study

Comparison of Efficacy and Safety of Lupin’s Pegfilgrastim with Neulastim® as an Adjunct to Chemotherapy in Patients with Non Myeloid Malignancies: A Randomised Phase III Clinical Study

Introduction: Pegfilgrastim is indicated in patients receiving myelosuppressive anticancer drugs to reduce the Duration of Severe Neutropenia (DSN) and incidence of Febrile Neutropenia (FN). The efficacy and safety of a proposed Pegfilgrastim biosimilar should be compared with an approved biologic d...

Full description

Bibliographic Details
Main Authors: Minish Jain, Sharad Desai, Rajnish Nagarkar, Rakesh Neve, Unmesh Takalkar, Dhananjay Bakhle, Chirag Shah
Format: Article
Language:English
Published: JCDR Research and Publications Private Limited 2022-08-01
Series:Journal of Clinical and Diagnostic Research
Subjects:
absolute neutrophil count
biosimilars
febrile neutropenia
granulocyte colony-stimulating factor
therapeutic equivalence
Online Access:https://jcdr.net/articles/PDF/16768/57833_CE(AD)_F(KR)_PF1(AB_SL)_PFA(AB_KM)_PN(KM).pdf

Internet

https://jcdr.net/articles/PDF/16768/57833_CE(AD)_F(KR)_PF1(AB_SL)_PFA(AB_KM)_PN(KM).pdf

Similar Items